Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving...
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 12, 2024 /PRNewswire/ -- USA News Group News Commentary – The...
IRVINE, Calif., Dec. 12, 2024 /PRNewswire/ -- MaxScientific Inc., a global leader in the field of aging and longevity intervention,...
CDMO's Cell and Gene Center of Excellence Achieves fifth commercial viral vector product approval, and second overall from FDA in...
Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 OnTarget trial evaluating crofelemer for...
Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth...
STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage...
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug,...
The Company will review on Thursday, December 12th, at 12:00 p.m. EST. GARDEN CITY, NY, Dec. 11, 2024 (GLOBE NEWSWIRE)...
The ongoing obesity Phase 2 trial is a randomized, double-blind, placebo-controlled, dose finding, clinical trial to evaluate the safety and...
Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic...
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant...
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed...
Award honors the integration of genomics into critical illness coverage, enhancing the value of life and critical illness products for...
Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide...
Leading Contract Research Organization integrates H1’s Trial Landscape platform to optimize global site selection, enhance diversity efforts, and streamline operational...
Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT)...
PLANO, Texas, Dec. 9, 2024 /PRNewswire/ -- ESPN Events along with the Orlando Sports Foundation (OSF) announced that Jacksonville State...
Strong Eversense® 365 early launch indicators illustrated by largest number of new patient shipments and largest number of prescribing providers...
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies...